Analysts take a look at Amicus Therapeutics, Inc. (NASDAQ:FOLD) having this to say.

July 16, 2018 - By Kristin Houston

Amicus Therapeutics, Inc. (NASDAQ:FOLD) LogoInvestors sentiment increased to 1.83 in 2018 Q1. Its up 0.62, from 1.21 in 2017Q4. It is positive, as 12 investors sold Amicus Therapeutics, Inc. shares while 46 reduced holdings. 37 funds opened positions while 69 raised stakes. 214.13 million shares or 8.37% more from 197.59 million shares in 2017Q4 were reported.
Hudson Bay Mgmt Lp has invested 0.06% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Mutual Of America Cap Limited Liability Company has invested 0.05% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Perceptive Advisors Ltd Limited Liability Company has invested 8.44% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). J Goldman L P invested 0.05% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Connor Clark And Lunn Investment Mngmt Limited holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 11,514 shares. Barclays Public Limited Com reported 0% stake. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 11,925 shares in its portfolio. Moreover, Massachusetts Financial Ma has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Fred Alger Management stated it has 0.01% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). The Illinois-based First Midwest Financial Bank Trust Division has invested 0.07% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Us Bank De holds 0% or 814 shares in its portfolio. Price T Rowe Assocs Inc Md has 4.95M shares for 0.01% of their portfolio. Putnam Lc reported 86,330 shares. Royal Bank & Trust Of Canada invested in 318,869 shares or 0% of the stock. Thompson Davis And invested in 2,827 shares.

Since January 22, 2018, it had 3 buys, and 16 insider sales for $3.77 million activity. $160,000 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by MCGLYNN MARGARET G on Wednesday, May 16. Another trade for 25,000 shares valued at $375,000 was sold by Do Hung. 5,000 shares were sold by RAAB MICHAEL, worth $72,058. PERCEPTIVE ADVISORS LLC bought $4.55 million worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Monday, March 5. Quimi Daphne also sold $131,250 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Friday, March 9. 10,000 Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares with value of $156,292 were sold by Baird William D III.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 2 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amicus Therapeutics had 2 analyst reports since February 8, 2018 according to SRatingsIntel. Robert W. Baird maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Wednesday, February 7 with “Buy” rating. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Outperform” rating given on Thursday, February 8 by Leerink Swann. Below is a list of Amicus Therapeutics, Inc. (NASDAQ:FOLD) latest ratings and price target changes.

07/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $20.0 Maintain
08/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $20 New Target: $24 Maintain

The stock decreased 2.16% or $0.34 during the last trading session, reaching $15.41. About 891,992 shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 90.47% since July 16, 2017 and is uptrending. It has outperformed by 77.90% the S&P500.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company has market cap of $2.90 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. It currently has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

Another recent and important Amicus Therapeutics, Inc. (NASDAQ:FOLD) news was published by which published an article titled: “Amicus Therapeutics -10% on missed CMA in Europe” on June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.